BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 4617711)

  • 1. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
    Lieberman R; Epstein W; Fudenberg HH
    Int J Cancer; 1974 Sep; 14(3):401-16. PubMed ID: 4617711
    [No Abstract]   [Full Text] [Related]  

  • 2. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 4. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE; Levin AS; Wybran J
    Cell Immunol; 1976 Jan; 21(1):1-19. PubMed ID: 764975
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 8. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 9. Adoptive transfer and specific active immunization of patients with malignant melanoma.
    Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
    Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
    Mavligit G; Gutterman JU; McBride C; Hersh EM
    Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
    [No Abstract]   [Full Text] [Related]  

  • 18. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.
    Silverstein MJ; DeKernion J; Morton DL
    JAMA; 1974 Aug; 229(6):688. PubMed ID: 4408302
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunotherapy].
    Lejeune FJ; Bernheim JL; Vanwijck R
    Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
    [No Abstract]   [Full Text] [Related]  

  • 20. [Development in the immunotherapy of malignant melanoma].
    Tritsch H
    Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.